-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Keep forging ahead steadily! Shijiazhuang Fourth Pharmaceutical has ranked 45th on the 2019 Top 100 Chinese Chemical Pharmaceutical Companies list.
Category:
Time：2020-07-27
On July 22, the highly anticipated 2019 Top 100 Chinese Pharmaceutical Industry Rankings were officially released. Shijiazhuang No.4 Pharmaceutical Co., Ltd. successfully retained its position on the “2019 Top 100 Chinese Chemical Pharmaceutical Enterprises” list, ranking 45th thanks to its solid and comprehensive competitive strength.
On July 22, the highly anticipated 2019 Top 100 Chinese Pharmaceutical Industry Rankings were officially released. Shijiazhuang No.4 Pharmaceutical Co., Ltd. successfully retained its position on the “2019 Top 100 Chinese Chemical Pharmaceutical Enterprises” list, thanks to its solid and comprehensive competitive strength. The company ranked 45th, an improvement of five places compared to its 2018 ranking.
According to the introduction, the 2019 Top 100 Chinese Pharmaceutical Industry Rankings does not feature a single overall list. Instead, it is divided into five sub-lists: “Top 100 Chinese Chemical Pharmaceutical Companies,” “Top 100 Chinese Traditional Chinese Medicine Companies,” “Top 20 Chinese CRO (including CDMO) Companies,” “Top 20 Chinese Medical Device (including IVD) Companies,” and “Top 20 Chinese Biopharmaceutical Companies (including blood products, vaccines, insulin, etc.).” A total of 260 companies made the list.
This selection process focuses on the innovation-driven force and professional promotion capabilities of pharmaceutical manufacturing enterprises. The innovation-driven force is primarily assessed based on comprehensive R&D investment indicators, while the professional promotion capability is rigidly defined according to quantitative data from end-user markets—specifically, the final selection preferences of clinicians and patients. Ultimately, a quantitative analysis is conducted by integrating Minenet’s exclusive data on the three major end-user segments and six key market segments.
It is understood that since its inception in 2006, the Top 100 Chinese Pharmaceutical Industry List has been one of the most closely watched and authoritative pharmaceutical rankings in China for over a decade. Shijiazhuang Fourth Pharmaceutical has been consistently included on the list for many years, with its overall ranking steadily improving. This latest inclusion on the list once again recognizes the company’s comprehensive strengths in innovation and market performance.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license